Product logins

Find logins to all Clarivate products below.


AstraZeneca | Genitourinary | Strategy and Drivers | 2024

The Company Franchise Analysis (CFA) provides a comprehensive evaluation of the franchise, including benchmarking, strategic insights, and an overview of marketed products. It highlights key market drivers and offers a detailed pipeline and sales analysis, along with information on deals and significant events. This profile aims to deliver a thorough understanding of the market dynamics and the strategic positioning of the franchise’s drugs.

Related Market Assessment Reports

Report
Genitourinary Syndrome of Menopause – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of GSM comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy,…
Report
Squamous Cell Carcinoma of the Head and Neck | Disease Landscape & Forecast | G7 | 2024
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Ovarian Cancer | Disease Landscape & Forecast | G7 | 2024
The treatment of ovarian cancer has been transformed by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (Zejula; GSK), and…
Report
Non-Small-Cell Lung Cancer | Disease Landscape & Forecast | G7 | 2024
The multibillion-dollar NSCLC therapy market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as Keytruda (Merck & Co.), which…
Report
Systemic Lupus Erythematosus – Geographic Focus: China – China In-Depth – Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs or systems in the body. The treatment goals of physicians who manage SLE patients differ depending on…